Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23103479 | 0.91 | HRH3 (0.42) | HRH3CHRNA7GPR119CYP2D6KCNH2 | |
| SCHEMBL525238 | 0.91 | HRH3 (0.42) | HRH3CHRNA7GPR119CYP2D6KCNH2 | |
| SCHEMBL16869392 | 0.91 | HRH3 (0.42) | HRH3CHRNA7GPR119CYP2D6KCNH2 | |
| SCHEMBL22876969 | 0.89 | TSHR (0.43) | HRH3CHRNA7GPR119CYP2D6KCNH2 | |
| SCHEMBL12026451 | 0.87 | HRH3 (0.40) | HRH3 | |
| SCHEMBL2737401 | 0.84 | — | — | |
| SCHEMBL105168 | 0.84 | — | — | |
| SCHEMBL438971 | 0.84 | — | — | |
| SCHEMBL24733191 | 0.83 | CHRNA7 (0.39) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 | |
| SCHEMBL24734655 | 0.83 | CHRNA7 (0.39) | HRH3CHRNA7CYP2D6KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1023 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106741-A | Alcohol dehydrogenase mutant and application thereof | 清华大学 | 2023-11-24 | — | — | CN | claimed |
| CN-115260326-B | Method for texturing surface of monocrystalline silicon by using alkali | 绍兴拓邦新能源股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115260326-A | Method for texturing surface of monocrystalline silicon by using alkali | 绍兴拓邦新能源股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| EP-2579872-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2011133733-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | claimed |
| EP-1737823-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2007-01-03 | — | — | EP | claimed |
| WO-2005103002-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| EP-1115707-B1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | claimed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | HRH3 409/4885CHRNA7 778/4885GPR119 861/4885 |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | ACSL5, ACSL3, ACSL6 | HRH3 2439/4885CHRNA7 2430/4885GPR119 282/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | HRH3 259/4885CHRNA7 662/4885GPR119 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.